NLRP3 and pulmonary fibrosis: Several preclinical studies in pulmonary fibrosis demonstrated efficacy using siRNA formulations aimed at silencing the expression of collagen‐specific chaperone heat shock protein 47 (HSP47),[9] Janus kinase type 2 (JAK 2),[10] E1A binding protein P300 (EP300),[11] plasminogen activator inhibitor‐1 (PAI‐1),[12] and NLR family pyrin domain containing 3 (NLRP3).[13] Related to this, two human clinical trials have used siRNA inhalation strategies to treat respiratory syncytial virus (RSV) (ALN‐RSV01)[14] and asthma (Excellair) via Syk silencing.[15]